Navigation Links
Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer
Date:9/10/2009

r earlier
  • The reaction was mild in most patients, resolving in 1 to 2 weeks
  • The reaction can be severe and debilitating in some patients, resulting in discontinuation of therapy
  • DOXIL is an irritant, not a vesicant; use precautions to avoid extravasation
  • DOXIL can cause fetal harm when used during pregnancy
  • Recall reaction has occurred with DOXIL administration after radiotherapy
  • DOXIL may interact with drugs known to interact with the conventional formulation of doxorubicin HCl
  • In patients with recurrent ovarian cancer, the most common all-grade adverse reactions (ARs) >20% (DOXIL vs topotecan, respectively) included: asthenia (40% vs 51%), fever (21% vs 31%), nausea (46% vs 63%), stomatitis (41% vs 15%), vomiting (33% vs 44%), diarrhea (21% vs 35%), anorexia (20% vs 22%), dyspnea (15% vs 23%), HFS (51% vs 1%), and rash (29% vs 12%)
    • In addition, 19% vs 52.3% reported alopecia (all grades)
    • Grade 3/4 hematologic ARs reported in >5% (DOXIL vs topotecan, respectively) were neutropenia (12% vs 76%) and anemia (6% vs 29%)
  • In patients with multiple myeloma, the most common all-grade ARs >20% (VELCADE plus DOXIL vs VELCADE, respectively) included: neutropenia (36% vs 22%), thrombocytopenia (33% vs 28%), anemia (25% vs 21%), fatigue (36% vs 28%), pyrexia (31% vs 22%), asthenia (22% vs 18%), nausea (48% vs 40%), diarrhea (46% vs 39%), vomiting (32% vs 22%), constipation (31% vs 31%), mucositis/stomatitis (20% vs 5%), peripheral neuropathy (42% vs 45%), neuralgia (17% vs 20%), and rash (22% vs 18%)
    • In addition, 19% vs <1% reported HFS
  • In patients with AIDS-related Kaposi's sarcoma, ARs reported in greater than or equal to 5% of DOXIL-treated patients were: neutropenia (ANC <1000/mm3, 46%; <500/mm
    '/>"/>

  • SOURCE Centocor Ortho Biotech Products, L.P.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
    2. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
    3. Centocor/Janssen-Cilags Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
    4. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
    5. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
    6. GeneNews provides Centocor access to its osteoarthritis program
    7. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)
    8. Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
    9. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
    10. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
    11. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/31/2015)... 31, 2015 Materials in Society ...   June 30 2015   Elsevier , ... and services and publishing home of Materials Today , ... the Materials in Society  Lecture Series . ... 8 th International Conference on Materials for Advanced Technologies ...
    (Date:3/31/2015)... 2015  Bayer HealthCare (Bayer) has expanded its ... of Technology (MIT) and Harvard University to include ... this new part of the alliance is to ... new cardiovascular therapies. "We are excited ... to the area of cardiovascular genomics to discover ...
    (Date:3/31/2015)... NEW YORK , March 31, 2015 ... a biopharmaceutical company advancing protein biologic therapies and ... Korean marketing partner, Hanmi Pharmaceutical Co., Ltd ("Hanmi") ... from the country,s Ministry of Food and Drug ... Institute (KTR) for MuGard, its oncology supportive-care treatment ...
    (Date:3/31/2015)... 2015 Today, Cryos International, the world’s ... their U.S. facilities and inventory from New York City ... experience, Cryos’ relocation is a reflection of their increasing ... Orlando was completed during the first weekend of spring, ... place on April 6. The new facility in the ...
    Breaking Biology Technology:Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 2Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 3Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 2Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 3PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3Cryos International Completes Groundbreaking Sperm Migration to Orlando, Florida 2
    ... EXTON, Pa., Oct. 2 Othera Pharmaceuticals, ... patient-administered,products for ophthalmology, oncology, and inflammatory disease, ... MD, FACP, as Chief,Scientific Officer effective immediately. ... development, integration and execution of Othera,s research,and ...
    ... BEIJING and CLAREMONT, Calif., Oct. 2 Kiwa,Bio-Tech Products ... Tianjin Kiwa Feed Limited Liability Company, located in,Wuqing District ... the,month of September. Mr. Wei Li, Chairman and ... in volume of Kiwa,s bio-feed products to approximately 7,550 ...
    ... Posters at Medical Conference in San Diego, ... October 4 ... - 7, 2007 -, CHICAGO, Oct. ... the,discovery, development and commercialization of novel drugs in the,therapeutic areas of infection, cancer and inflammation, ...
    Cached Biology Technology:Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer 2Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer 3Kiwa Bio-Tech Ships 2,700 Tons of Bio-feed in One Month 2Advanced Life Sciences to Present Data from Selected Cethromycin Clinical Trials at the 45th Annual Meeting of the Infectious Diseases Society of America 2Advanced Life Sciences to Present Data from Selected Cethromycin Clinical Trials at the 45th Annual Meeting of the Infectious Diseases Society of America 3
    (Date:3/12/2015)... VIEW, Calif. , March 12, 2015 /PRNewswire/ ... with Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: ... Manager Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... in order to compete in several different markets ... market is currently witnessing an uptrend. ...
    (Date:3/10/2015)... , March 10, 2015   Tute Genomics ... has been selected by next-generation sequencing company PrimBio ... whole exome and targeted gene panel interpretation. ... has adopted the most current technologies to support the ... research. The company offers two types of exome sequencing ...
    (Date:3/2/2015)... JOSE, Calif. , March 2, 2015 /PRNewswire/ ... the leading developer of human interface solutions, today ... technology that is designed to enable rapid and ... Natural ID™ module for gaming is a turnkey ... ODMs the ability to quickly integrate fingerprint ID ...
    Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
    ... FirstMark, the diagnostic division of GenWay Biotech, Inc., is ... and presenting at the San Diego Academy of Family ... 22-24. FirstMark will showcase the groundbreaking research and data ... first and only multiple biomarker blood test on the ...
    ... life, but for those species that do, wildlife biologists have ... relationships: greater longevity and breeding success, according to a study ... published in Behavioral Ecology . The study,s authors ... lose their mate, their chances for survival are greatly diminished. ...
    ... ointment, light on, light off that,s how easy it ... the majority of patients suffer severe pain during the so-termed ... can be so painful has now been uncovered by researchers ... signalling molecules secreted by the cancer cells. "The results may ...
    Cached Biology News:FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium 2Black brant geese show lifetime relationship good for goose and gander 2Double the pain: RUB biologists find the cause of pain in the treatment of fair skin cancer 2
    Request Info...
    ... Monoclonal Mouse Antibody to Cytokeratin 5 / ... a high molecular weight, basic type of ... the superficial cell layers of stratified epithelia ... and in mesothelial cells and mesothelioma. Cytokeratin ...
    Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
    Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
    Biology Products: